119 related articles for article (PubMed ID: 7646913)
1. A case for synchronous reduction of testicular androgen, adrenal androgen and prolactin for the treatment of advanced carcinoma of the prostate.
Rana A; Habib FK; Halliday P; Ross M; Wild R; Elton RA; Chisholm GD
Eur J Cancer; 1995 Jun; 31A(6):871-5. PubMed ID: 7646913
[TBL] [Abstract][Full Text] [Related]
2. Androgen suppression by hydrocortisone without aminoglutethimide in orchiectomised men with prostatic cancer.
Plowman PN; Perry LA; Chard T
Br J Urol; 1987 Mar; 59(3):255-7. PubMed ID: 3567487
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of total versus partial androgen blockade in the treatment of advanced prostatic cancer.
Schulze H; Kaldenhoff H; Senge T
Urol Int; 1988; 43(4):193-7. PubMed ID: 2973169
[TBL] [Abstract][Full Text] [Related]
4. Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen.
Narimoto K; Mizokami A; Izumi K; Mihara S; Sawada K; Sugata T; Shimamura M; Miyazaki K; Nishino A; Namiki M
Int J Urol; 2010 Apr; 17(4):337-45. PubMed ID: 20202011
[TBL] [Abstract][Full Text] [Related]
5. [Combined anti-androgen treatment in adenocarcinoma of the prostate: first use of a new therapeutically efficacious principle in hormone-dependent cancer].
Labrie F; Dupont A; Bélanger A; Lacourcière Y; Monfette JE; Monfette G
Ann Urol (Paris); 1986; 20(2):98-106. PubMed ID: 2940959
[TBL] [Abstract][Full Text] [Related]
6. Advantages of total androgen blockade in the treatment of advanced prostate cancer.
Geller J; Albert J; Vik A
Semin Oncol; 1988 Apr; 15(2 Suppl 1):53-61. PubMed ID: 3285484
[TBL] [Abstract][Full Text] [Related]
7. Pituitary adrenal and gonadal endocrine suppression for the primary treatment of prostate cancer.
Williams G; Asopa R; Abel PD; Smith C
Br J Urol; 1990 May; 65(5):504-8. PubMed ID: 2141289
[TBL] [Abstract][Full Text] [Related]
8. The effects of aminoglutethimide and hydrocortisone, alone and combined, on androgen levels in post-orchiectomy prostatic cancer patients.
Dowsett M; Shearer RJ; Ponder BA; Malone P; Jeffcoate SL
Br J Cancer; 1988 Feb; 57(2):190-2. PubMed ID: 3358910
[TBL] [Abstract][Full Text] [Related]
9. [Bromocriptine for palliation of advanced prostatic carcinoma. Experimental and clinical profile of a drug (author's' transl)].
Jacobi GH; Altwein JE
Urol Int; 1979; 34(4):266-90. PubMed ID: 89747
[TBL] [Abstract][Full Text] [Related]
10. Maximal androgen blockade versus total androgen suppression.
Dumez H; Van Poppel H; Baert L; Paridaens R
Acta Urol Belg; 1997 Mar; 65(1):49-54. PubMed ID: 9175283
[TBL] [Abstract][Full Text] [Related]
11. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
Boccon-Gibod L; Fournier G; Bottet P; Marechal JM; Guiter J; Rischman P; Hubert J; Soret JY; Mangin P; Mallo C; Fraysse CE
Eur Urol; 1997; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
[TBL] [Abstract][Full Text] [Related]
12. Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma.
Figg WD; Kroog G; Duray P; Walther MM; Patronas N; Sartor O; Reed E
Cancer; 1997 May; 79(10):1964-8. PubMed ID: 9149024
[TBL] [Abstract][Full Text] [Related]
13. Comparison of various hormonal therapies for prostatic carcinoma.
Geller J; Albert JD
Semin Oncol; 1983 Dec; 10(4 Suppl 4):34-41. PubMed ID: 6199846
[TBL] [Abstract][Full Text] [Related]
14. Plasma androgen levels after subcapsular orchiectomy or estrogen treatment for prostatic carcinoma.
Vermeulen A; Schelfhout W; De Sy W
Prostate; 1982; 3(2):115-21. PubMed ID: 6211662
[TBL] [Abstract][Full Text] [Related]
15. Adrenal steroid levels in castrated men with prostatic carcinoma treated with aminoglutethimide plus hydrocortisone.
Ahmann FR; Crawford ED; Kreis W; Levasseur Y
Cancer Res; 1987 Sep; 47(17):4736-9. PubMed ID: 3621171
[TBL] [Abstract][Full Text] [Related]
16. Treatment of advanced prostatic cancer with anti-androgens alone and a combination of anti-androgen with anti-prolactin--a pilot study.
Hoogendijk E; de Voogt HJ
Urol Res; 1986; 14(3):129-31. PubMed ID: 2944268
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of bromocriptine in patients with androgen-independent prostate cancer.
Horti J; Figg WD; Weinberger B; Kohler D; Sartor O
Oncol Rep; 1998; 5(4):893-6. PubMed ID: 9625840
[TBL] [Abstract][Full Text] [Related]
18. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.
Nair B; Wilt T; MacDonald R; Rutks I
Cochrane Database Syst Rev; 2002; (1):CD003506. PubMed ID: 11869665
[TBL] [Abstract][Full Text] [Related]
19. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
Pummer K; Lehnert M; Stettner H; Hubmer G
Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
[TBL] [Abstract][Full Text] [Related]
20. Combination treatment versus LHRH alone in advanced prostatic cancer.
Ferrari P; Castagnetti G; Ferrari G; Baisi B; Dotti A
Urol Int; 1996; 56 Suppl 1():13-7. PubMed ID: 8776812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
